Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00051909
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Must have a clinical diagnosis of Alzheimer's Disease
- Must be at least 50 years of age
- Must fluently read and speak English
- Must have a reliable caregiver
Exclusion Criteria
- Has serious health problems other than Alzheimer's Disease
- Cannot swallow whole pills
- Has had a menstrual period in the last two years
- Takes insulin for diabetes
- Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method